Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

mAbs

Volumn 4, Issue 2, 2012, Pages 243-255

  Zheng, Yanan ^a   Tesar, Devin B ^a   Benincosa, Lisa ^b   Birnböck, Herbert ^c   Boswell, C Andrew ^a   Bumbaca, Daniela ^a   Cowan, Kyra J ^a   Danilenko, Dimitry M ^a   Daugherty, Ann L ^a   Fielder, Paul J ^a   Grimm, Hans Peter ^c   Joshi, Amita ^a   Justies, Nicole ^c   Kolaitis, Gerry ^b   Lewin Koh, Nicholas ^a   Li, Jing ^a   McVay, Sami ^a   O'Mahony, Jennifer ^a   Otteneder, Michael ^c   Pantze, Michael ^c   Putnam, Wendy S ^a   Qiu, Zhihua J ^a   Ruppel, Jane ^a   Singer, Thomas ^c   Stauch, Oliver ^c   Theil, Frank Peter ^a   Visich, Jennifer ^a   Yang, Jihong ^a   Ying, Yong ^a   Khawli, Leslie A ^a   Richter, Wolfgang F ^c   more..

^a GENENTECH INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Animal model; mAb IgG; Minipig; Neonatal Fc receptor (FcRn); Pharmacokinetics; Subcutaneous bioavailability

Indexed keywords

ADALIMUMAB; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EXPERIMENTAL MODEL; EXPERIMENTAL PIG; FEMALE; HUMAN VERSUS ANIMAL COMPARISON; ISOELECTRIC POINT; MALE; MINIPIG; NONHUMAN; PREDICTIVE VALUE; SPECIES DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SWINE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MODELS, IMMUNOLOGICAL; SWINE; SWINE, MINIATURE;

EID: 84863230445     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19387     Document Type: Article

References (61)

1. Green MD, Hartsough M. The Role of Pharmacokinetics and Pharmacodynamics in Selecting a Relevant Species. Preclinical Safety Evaluation of Biopharmaceuticals: John Wiley & Sons, Inc. 2007;277-91.
2. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010; 24:23-39; PMID:20055530; http://dx.doi.org/10.2165/11530560-000000000-00000.
3. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007;6:120-6; PMID:17268483; http://dx.doi.org/10.1038/nrd2242.
4. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/ mabs.3.1.13799.
5. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382-402; PMID:19837907; http://dx.doi.org/10.1177/0091270009337134.
6. Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011; 26:423-30; PMID:21606605; http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-011.
7. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 2010; 12:461-70; PMID:20677097.
8. McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2005; 2:89-96; http://dx.doi.org/10.1016/j.ddtec.2005.05.006.
9. Porter CJ, Charman WN. Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev 2001; 50:1-2; PMID:11489330; http://dx.doi.org/10.1016/S0169-409X(01)00146-6.
10. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89:297-310; PMID:10707011; http://dx.doi.org/10.1002/(SICI)1520-6017(200003)89:3〈297::AID-JPS2〉3. 0.CO;2-P.
11. Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, Johnston DG. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf) 1991; 35:409-12; PMID:1814654; http://dx.doi.org/10.1111/j.1365-2265.1991.tb03557.x.
12. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4:427-40; PMID:17683255; http://dx.doi.org/10.1517/17425247.4.4.427.
13. Forster R, Bode G, Ellegaard L, van der Laan JW; Steering Group of the RETHINK Project. The RETHINK project - minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment. J Pharmacol Toxicol Methods 2010; 62:158-9; PMID:20685395; http://dx.doi.org/10.1016/j. vascn.2010.05.003.
14. Dolgin E. Minipig, minipig, let me in. Nat Med 2010; 16:1349; PMID:21135823; http://dx.doi.org/10.1038/nm1210-1349a.
15. Bronaugh RL, Stewart RF, Congdon ER. Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol Appl Pharmacol 1982; 62:481-8; PMID:7071863; http://dx.doi.org/10.1016/0041-008X(82)90149-1.
16. Washer G, Makin A. Minipigs as an alternative nonrodent species in toxicology and safety studies. Seattle: Society of Toxicology 2008.
17. Ellegaard L, Cunningham A, Edwards S, Grand N, Nevalainen T, Prescott M, et al.; Steering Group of the RETHINK Project. Welfare of the minipig with special reference to use in regulatory toxicology studies. J Pharmacol Toxicol Methods 2010; 62:167-83; PMID:20621655; http://dx.doi.org/10.1016/j.vascn.2010. 05.006.
18. Qvist MH, Hoeck U, Kreilgaard B, Madsen F, Frokjaer S. Evaluation of Göttingen minipig skin for transdermal in vitro permeation studies. Eur J Pharm Sci 2000; 11:59-68; PMID:10913754; http://dx.doi.org/10.1016/S0928- 0987(00)00091-9.
19. Xing QF, Lin S, Chien YW. Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism. J Control Release 1998; 52:89-98; PMID:9685939; http://dx.doi.org/10.1016/S0168-3659(97)00190-9.
20. Nobilis M, Kopecký J, Kvetina J, Svoboda Z, Pour M, Kunes J, et al. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J Pharm Biomed Anal 2003; 32:641-56; PMID:12899954; http://dx.doi.org/10.1016/S0731-7085(03)00171-7.
21. van Mierlo G, Cnubben NLA, Wouters D, Wolbink GJ, Gandsrup NC, et al. Immunogenicity testing of Adalimumab and Infliximab in Göttingen Minipigs. Society of Toxicology. Washington DC: Society of Toxicology 2011.
22. Penninks A, Wolthoorn J, Cnubben N, Gandsrup NC, van Mierlo G. Immunogenicity testing of Kineret in Göttingen minipigs. Society of Toxicology. Washington DC: Society of Toxicology 2011.
23. Lin S, Chen LL, Chien YW. Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs. J Pharmacol Exp Ther 1998; 286:959-66; PMID:9694956.
24. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011; 28:107-16; PMID:20354765; http://dx.doi.org/10.1007/s11095-010-0123-9.
25. Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 2000; 293:248-59;PMID:10734176.
26. Jacobs A. Use of nontraditional animals for evaluation of pharmaceutical products. Expert Opin Drug Metab Toxicol 2006; 2:345-9; PMID:16863438; http://dx.doi.org/10.1517/17425255.2.3.345.
27. Sharma R, Wang W, Rasmussen JC, Joshi A, Houston JP, Adams KE, et al. Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol 2007; 292:3109-18; PMID:17307997; http://dx.doi.org/10.1152/ajpheart.01223.2006.
28. Hammond SA, Tsonis C, Sellins K, Rushlow K, Scharton-Kersten T, Colditz I, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000; 43:45-55; PMID:10967220; http://dx.doi.org/10.1016/S0169-409X(00)00076-4.
29. Rose EH, Vistnes LM, Ksander GA. The panniculus carnosus in the domestic pig. Plast Reconstr Surg 1977; 59:94-7; PMID:831245; http://dx.doi.org/10.1097/ 00006534-197701000-00017.
30. Kawamata S, Ozawa J, Hashimoto M, Kurose T, Shinohara H. Structure of the rat subcutaneous connective tissue in relation to its sliding mechanism. Arch Histol Cytol 2003; 66:273-9; PMID:14527168; http://dx.doi.org/10.1679/aohc.66. 273.
31. Sidhu SS. Full-length antibodies on display. Nat Biotechnol 2007; 25:537-8; PMID:17483836; http://dx.doi.org/10.1038/nbt0507-537.
32. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155.
33. 1 in the circulation of mice. Scand J Immunol 1994; 40:457-65; PMID:7939418; http://dx.doi.org/10.1111/j.1365-3083. 1994.tb03488.x.
34. 1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182.
35. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 2007; 179:4580-8; PMID:17878355.
36. 1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296.
37. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81-8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X.
38. 1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110.
39. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21:2153-63; PMID:21053952; http://dx.doi.org/10.1021/ bc100261d.
40. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2 and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm 2002; 17:359-70; PMID:12396700; http://dx.doi.org/10.1089/ 108497802760363150.
41. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx.doi.org/10.1093/ protein/gzq009.
42. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093-5; PMID:8378254; http://dx.doi.org/10.1023/A: 1018943613122.
43. Simianer H, Köhn F. Genetic management of the Göttingen Minipig population. J Pharmacol Toxicol Methods 2010; 62:221-6; PMID:20570747; http://dx.doi.org/10.1016/j.vascn.2010.05.004.
44. van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C; Steering Group of the RETHINK Project. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods 2010; 62:184-95; PMID:20601024; http://dx.doi.org/10.1016/j. vascn.2010.05.005.
45. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31:253-63; PMID:20437464.
46. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 2007; 35:1672-8; PMID:17576810; http://dx.doi.org/10.1124/dmd.107.015248.
47. Leu AJ, Berk DA, Yuan F, Jain RK. Flow velocity in the superficial lymphatic network of the mouse tail. Am J Physiol 1994; 267:1507-13; PMID:7943396.
48. Berk DA, Swartz MA, Leu AJ, Jain RK. Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 1996; 270:330-7; PMID:8769769.
49. Modi S, Stanton AW, Mortimer PS, Levick JR. Clinical assessment of human lymph flow using removal rate constants of interstitial macromolecules: a critical review of lymphoscintigraphy. Lymphat Res Biol 2007; 5:183-202; PMID:18035937; http://dx.doi.org/10.1089/lrb.2007.5306.
50. Modi S, Stanton AW, Svensson WE, Peters AM, Mortimer PS, Levick JR. Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy. J Physiol 2007; 583:271-85; PMID:17569739; http://dx.doi.org/10.1113/jphysiol.2007.130401.
51. Fischer M, Franzeck UK, Herrig I, Costanzo U, Wen S, Schiesser M, et al. Flow velocity of single lymphatic capillaries in human skin. Am J Physiol 1996; 270:358-63; PMID:8769772.
52. Vugmeyster Y, Szklut P, Wensel D, Ross J, Xu X, Awwad M, et al. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 2011; 28:1696-706; PMID:21424161; http://dx.doi.org/10.1007/s11095-011-0405-x.
53. Bumbaca D, Wong A, Drake E, Reyes AE, 2nd, Lin BC, Stephan JP, et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011; 3:376-86; PMID:21540647; http://dx.doi.org/10.4161/mabs.3.4.15786.
54. Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptorimmunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 1999; 27:21-5; PMID:9884305.
55. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15:637-40; PMID:9219265; http://dx.doi.org/10.1038/nbt0797-637.
56. Zhao Y, Kacskovics I, Zhao Z, Hammarström L. Presence of the di-leucine motif in the cytoplasmic tail of the pig FcRn alpha chain. Vet Immunol Immunopathol 2003; 96:229-33; PMID:14592735; http://dx.doi.org/10.1016/ j.vetimm.2003.08.006.
57. Lavielle M, Mesa H, Chatel K. MONOLIX 3.1 (http://software.monolix.org/ sdoms/software/). INRIA 2009.
58. Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, et al. Construction and characterization of an active factor VIII variant lacking the central onethird of the molecule. Biochemistry 1986; 25:8343-7; PMID:3030393; http://dx.doi.org/10.1021/bi00374a001.
59. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol 1991; 147:1548-56; PMID:1715362.
60. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29:2288-98; PMID:12415583.
61. Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factoralpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem 1999; 275:98-108; PMID:10542114; http://dx.doi.org/10.1006/abio.1999.4275.